Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 3
- Registration Number
- NCT02353572
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT02342782
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
- Conditions
- Interventions
- Drug: Fludarabine PhosphateDrug: MelphalanRadiation: Intensity-Modulated Radiation TherapyRadiation: Total Marrow IrradiationProcedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Peripheral Blood Stem Cell TransplantationProcedure: Allogeneic Bone Marrow TransplantationDrug: TacrolimusDrug: Mycophenolate MofetilOther: Laboratory Biomarker Analysis
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 30
- Registration Number
- NCT02333162
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT02331368
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- University College, London
- Target Recruit Count
- 11
- Registration Number
- NCT02310997
- Locations
- 🇬🇧
Nottingham City Hospital, Nottingham, United Kingdom
🇬🇧Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧University College London Hospital, London, Greater London, United Kingdom
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 100
- Registration Number
- NCT02295722
- Locations
- 🇨🇦
Tom Baker Cancer Center, Calgary, Alberta, Canada
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
- Conditions
- Interventions
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02259348
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: CyclophosphamideDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: MelphalanDrug: MethotrexateDrug: Mycophenolate MofetilDrug: RuxolitinibDrug: TacrolimusRadiation: Total-Body IrradiationProcedure: Umbilical Cord Blood Transplantation
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT02251821
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT02206425
- Locations
- 🇺🇸
James Berenson, MD, Inc, West Hollywood, California, United States
🇺🇸cCARE Fresno, Fresno, California, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
- Conditions
- Interventions
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT02199041
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.